

11. (Amended) Pharmaceutical composition according to Claim 10, [characterized in that] wherein said polypeptides [have the characteristics defined in Claims 2 to 9] are derived from the E6 protein, from the E7 protein or from the E6 and E7 proteins of a papillomavirus.

Claim 12, line 2, change "or 11, characterized in that" to --, wherein--.

Claim 13, line 2, change "characterized in that" to --wherein--.

Claim 14, line 2, change "characterized in that" to --wherein--.

Claim 15, line 2, change "or 14, characterized in that" to --, wherein--.

Claim 16, line 2, change "or 15, characterized in that" to --, wherein--.

Claim 17, line 2, change "or 15, characterized in that" to --, wherein--.

Claim 18, lines 1-2, change "one of Claims 10 to 17" to --Claim 10--.

Claim 19, lines 1-2, change "one of Claims 10 to 17" to --Claim 10--.

Claim 20, lines 1-2, change "one of Claims 10 to 19, characterized in that" to --Claim 10, wherein--.

Kindly add the following claims:

--23. A method for the treatment or prevention of dysplasia or cancer of the neck of the uterus, comprising administering an effective amount of the pharmaceutical composition of claim 10 to a patient in need of such treatment.

24. A method for the prevention or treatment of a papilloma-virus infection, comprising administering an effective amount of the pharmaceutical composite of claim 10 to a patient in need of such treatment.

25. Pharmaceutical composition according to Claim 10, wherein said early region polypeptide is a nononcogenic variant of the E6 and/or E7 protein of a papillomavirus.
26. Pharmaceutical composition according to Claim 10, wherein said late region polypeptide is derived from the L1 protein, the L2 protein or from the L1 and L2 proteins.
27. Pharmaceutical composition according to Claim 10, wherein said polypeptide having immunostimulatory activity is selected from the group consisting of interleukin-2, interleukin-7, interleukin-12 and the co-adhesion molecules B7.1 and B7.2.
28. Pharmaceutical composition according to Claim 27, wherein said polypeptide having immunostimulatory activity is derived from interleukin-2.
29. Pharmaceutical composition according to Claim 27, wherein said polypeptide having immunostimulatory activity is derived from the molecule B7.1.
30. Pharmaceutical composition according to Claim 10, comprising:
- (1) a polypeptide from the E6 region, a polypeptide from the E7 region, a polypeptide from the L1 region and a polypeptide from the L2 region of a papillomavirus;
  - (2) a polypeptide from the E6 region, a polypeptide from the E7 region of a papillomavirus and a polypeptide derived from interleukin-2;

31. (3) a polypeptide from the E6 region, a polypeptide from the E7 region of a papillomavirus and a polypeptide derived from the molecule B7.1;
- (4) a polypeptide from the E6 region, a polypeptide from the E7 region of a papillomavirus, a polypeptide derived from the molecule B7.1 and a polypeptide derived from interleukin-2;
- (5) a polypeptide from the E6 region, a polypeptide from the E7 region, a polypeptide from the L1 region, a polypeptide from the L2 region of a papillomavirus and a polypeptide derived from interleukin-2;
- (6) a polypeptide from the E6 region, a polypeptide from the E7 region, a polypeptide from the L1 region, a polypeptide from the L2 region of a papillomavirus and a polypeptide derived from the molecule B7.1; or
- (7) a polypeptide from the E6 region, a polypeptide from the E7 region, a polypeptide from the L1 region, a polypeptide from the L2 region of a papillomavirus, a polypeptide derived from the molecule B7.1 and a polypeptide derived from interleukin-2.

31. Pharmaceutical composition according to Claim 10, wherein the papillomavirus is selected from the group consisting of HPV-16, HPV-18, HPV-31, HPV-33 and HPV-45.--